HPLC method for determination of verapamil in human plasma after solid-phase extraction

Ivanova, Violeta; Zendelovska, Dragica; Стефова, Марина; Stafilov, Trajče

doi:10.1016/j.jbbm.2007.09.009

Cited by 23 publications

(15 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The methods used for verapamil quantification in plasma samples include GC (Hege, 1979), GC/MS (Hynning et al, 1988), HPLC with fluorescence (Sawicki, 2001;Jhee et al, 2005) or ultraviolet detection (Lau-Cam and Piemontese, 1998;Ivanova et al, 2008) and liquid chromatographic-mass spectrometric methods (Von Richter et al, 2000;Hedeland et al, 2004). All of the above methods require a large volume (at least 500 mL) of plasma sample.…”

Section: Introductionmentioning

confidence: 99%

An LC‐MS/MS method for simultaneous determination of vincristine and verapamil in rat plasma after oral administration of a dual agent formulation

Ling

Zhang

Sun

et al. 2010

Biomedical Chromatography

View full text Add to dashboard Cite

A rapid and sensitive method for simultaneous determination of vincristine and verapamil in rat plasma was first developed and validated, using high-performance liquid chromatography-tandem mass spectrometry (LC-MS/MS) in multiple reaction monitoring (MRM) mode via electrospray ionization (ESI). The method, which required a small sample volume (25 µL) of plasma, was linear in the concentration range of 0.5-500 ng/mL for vincristine and 0.1-100.0 ng/mL for verapamil. Finally, the method was successfully employed in a pharmacokinetic study of vincristine and verapamil in rats after an oral administration of a dual-agent formulation containing vincristine and verapamil.

show abstract

Section: Introductionmentioning

confidence: 99%

An LC‐MS/MS method for simultaneous determination of vincristine and verapamil in rat plasma after oral administration of a dual agent formulation

Ling

Zhang

Sun

et al. 2010

Biomedical Chromatography

View full text Add to dashboard Cite

show abstract

“…The eluents were monitored at 278 nm (AUFS = 1). The injection volume was 20 µL and eluted at a flow rate of 1.0 mL min −1 at 30 °C …”

Section: Methodsmentioning

confidence: 99%

Multifunctional Shell–Core Nanoparticles for Treatment of Multidrug Resistance Hepatocellular Carcinoma

Wang

Zhang

Liao

et al. 2018

Adv Funct Materials

View full text Add to dashboard Cite

Multidrug resistance (MDR) is the main obstruction against the chemotherapy for hepatocellular carcinoma. Herein, a biodegradable multifunctional tumor-targeted core-shell structural nanocarrier (RGD peptide functionalized nanoparticles, RGD-NPs) is reported for treating MDR hepatocellular carcinoma, which consists of three components: pH-triggered calcium phosphate shell, long circulation phosphatidylserine-polyethylene glycol (PS-PEG) core, and an active targeting ligand RGD peptide. Drug-resistance inhibitor (verapamil, VER) and chemotherapeutic agent (mitoxantrone, MIT) are separately encapsulated into the outer shell layer and inner core layer to obtain VER and MIT loaded RGD-NPs (VM-RGD-NPs). Due to the shell-core structure, the VER and MIT can release sequentially, thus synergistically weakening the efflux effect to MIT by MDR cells. Also, the calcium phosphate can trigger lysosomal escaping through the varied pH value. Together with the optimized internalization pathway in MDR tumor cells, the increased intracellular effective chemotherapeutic drug concentration can be realized, thus achieving the improved curative effect. In this system, the PEG extends the circulation time in vivo. Also, the peptide RGD distinctly increases the affinity to MDR tumors with respect to nontargeted nanoparticles. As a consequence, VM-RGD-NPs exhibit a significant synergistic effect toward the MDR hepatocellular carcinoma, providing a promising therapeutic approach for MDR tumor.

show abstract

“…12 In patients with hepatic insufficiency, metabolism is delayed and elimination half-life is prolonged up to 14-16 hours. These include spectrophotometry, 15 high performance liquid chromatography (HPLC) with spectrophotometric detection, [16][17][18][19][20][21] high performance thin layer chromatography, 22,23 and liquid chromatography-tandem mass spectrometry (LC-MS/MS). † These authors contributed equally to this work.…”

Section: Introductionmentioning

confidence: 99%

“…12 Many methods have been reported for the analysis of this combination or one of its components in pharmaceuticals or body fluids. These include spectrophotometry, 15 high performance liquid chromatography (HPLC) with spectrophotometric detection, [16][17][18][19][20][21] high performance thin layer chromatography, 22,23 and liquid chromatography-tandem mass spectrometry (LC-MS/MS). 24,25 Several pharmacokinetic studies have been reported for these drugs.…”

Section: Introductionmentioning

confidence: 99%

Comparative pharmacokinetics of trandolapril, its active metabolite, and verapamil in human plasma of Egyptian population using HPLC–MS/MS

Magdy

El‐Khatib

Hemdan

et al. 2018

Drug Testing and Analysis

View full text Add to dashboard Cite

Trandolapril and verapamil are commonly used antihypertensive drugs. However, there is a lack of available data on the change of their pharmacokinetics in patients with liver or kidney impairment and hence the need for dose adjustment. In this article, a high performance liquid chromatography-tandem mass spectrometry (HPLC-MS/MS) method was developed and validated for the monitoring of trandolapril, its active metabolite trandolaprilat, and verapamil in human plasma of patients with renal impairment and/or liver insufficiency. The chromatographic separation was achieved on a Gemini C reversed phase column using a gradient elution mode with a run time of 10 minutes. The mobile phase consisted of a mixture of methanol and 2% acetic acid. The electrospray ionization MS/MS analysis was performed in multiple reaction monitoring (MRM) mode. The assay was validated as per Food and Drug Administration (FDA) guidelines for bioanalytical method validation and proved to be suitable for the determination of therapeutic drug levels in plasma. The inter-group changes in pharmacokinetic data were compared to that of healthy volunteers. The comparison showed a significant difference in the pharmacokinetic parameters between the studied groups. The presented results exhibit the benefits of the proposed assay as a validated analytical tool for the continuous drug monitoring.

show abstract

HPLC method for determination of verapamil in human plasma after solid-phase extraction

Cited by 23 publications

References 17 publications

An LC‐MS/MS method for simultaneous determination of vincristine and verapamil in rat plasma after oral administration of a dual agent formulation

An LC‐MS/MS method for simultaneous determination of vincristine and verapamil in rat plasma after oral administration of a dual agent formulation

Multifunctional Shell–Core Nanoparticles for Treatment of Multidrug Resistance Hepatocellular Carcinoma

Comparative pharmacokinetics of trandolapril, its active metabolite, and verapamil in human plasma of Egyptian population using HPLC–MS/MS

Contact Info

Product

Resources

About